We rapidly transform existing drugs into impactful therapies by leveraging advanced carrier technologies and the 505(b)(2) pathway
Formulation development is slow and wasteful. With 9 out of 10 pipeline molecules facing bioavailability challenges, $200BN worth of products going off patent soon, and more complex molecules on the horizon, there is a pressing need for innovative and efficient formulation methods.
How?
Leveraging the power of our patented carriers and their digital twin models, we are rapidly and efficiently developing new bioavailable therapeutics, accelerating sustainable medicine development and improving global access to life-saving treatments.
Our carrier technologies can improve patient compliance and health outcomes by enhancing drug bioavailability and reducing dosage and frequency. Formulations can be rapidly made within days for various modalities.
Enhancing bioavailability, amorphous form stability and controlled-release
Optimising the delivery of beyond rule of 5 molecules e.g. PROTACs and molecular glues
Pushing the boundaries of what's deliverable
to mucosal/other tissues
Our core strategy is to develop clinically differentiated therapeutic assets at speed and resource-efficiency leveraging our IP-protected carriers, accompanying digital formulation models and an accelerated 505(b)(2) regulatory strategy.
Partnering with key stakeholders to accomplish our mission
